G2GBIO, a company specializing in drug delivery technology, announced on the 14th that it has signed a contract with German pharmaceutical company Boehringer Ingelheim for the additional formulation development of long-acting injectable drugs.
Earlier, the two companies signed their first agreement in February for the formulation development of a long-acting injectable treatment for a peptide new drug that Boehringer is developing. Boehringer provides G2GBIO with its peptide drug and related information, while G2GBIO utilizes its drug delivery platform InnoLAMP to develop a long-acting injectable formulation of the peptide new drug.
In this agreement, Boehringer will provide its new peptide drug and related information, and G2GBIO will design and develop a long-acting injectable formulation based on InnoLAMP for the drug.
InnoLAMP is a platform that can deliver various peptide drugs in micro-sized spherical particles (microspheres) with over 40% higher content, providing excellent bioavailability and minimizing injection site reactions.
G2GBIO is developing this technology into long-acting treatments for various diseases, including Alzheimer's, diabetes and obesity, and postoperative pain.
The company recently completed Phase 1 clinical trials for 1-month long-acting dementia treatments, 'GB-5001' and 'GB-5001A', in Canada and domestically, respectively. Along with this, a postoperative pain treatment, 'GB-6002', which lasts for more than 3 days, has also completed Phase 1 trials domestically. Ongoing projects include a central nervous system and metabolic disease candidate that includes a 1-month long-acting diabetes and obesity treatment, 'GB-7001.'
G2GBIO passed the preliminary examination for a technology-based listing last month and is expected to be listed on the KOSDAQ market on the 8th of next month.
Lee Hee-yong, CEO of G2GBIO, noted, "The continuous cooperation with global pharmaceutical companies and the push for a KOSDAQ listing reflect the market's trust in our technology," adding, "Through this collaboration, we will provide better treatment options to patients worldwide and strive to become a leading corporation in the global long-acting formulation market in the long run."